After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, ARQT falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Arcutis Biotherapeutics Inc is $2.11B. A total of 2.16 million shares were traded on the day, compared to an average of 1.71M shares.
In the most recent transaction, Watanabe Todd sold 9,625 shares of ARQT for 17.54 per share on Sep 08 ’25. After the transaction, the insider now owns 891,944 company shares. In a previous transaction on Sep 09 ’25, Watanabe Todd sold 504 shares at 17.52 per share. ARQT shares that the insider owns now total 891,440.
Among the insiders who bought shares, Watanabe Todd acquired of 504 shares on Sep 09 ’25 at a per-share price of $17.52. In another insider transaction, Matsuda Masaru sold 36,130 shares at $16.16 per share on Sep 04 ’25. Company shares held by the insider now total 161,234.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, ARQT has a high of $18.15 and a low of $8.03.
As of this writing, ARQT has an earnings estimate of -$0.1 per share for the current quarter. EPS was calculated based on a consensus of 5.0 estimates, with a high estimate of -$0.05 per share and a lower estimate of -$0.13. The company reported an EPS of -$0.33 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ARQT’s latest balance sheet shows that the firm has $387.06M in Cash & Short Term Investments as of fiscal 2021. There were $77.56M in debt and $33.33M in liabilities at the time. Its Book Value Per Share was $1.16, while its Total Shareholder’s Equity was $297.68M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ARQT is Buy with a score of 4.44.
